Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Biomerieux SA

BIM:PAR

Biomerieux SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)101.50
  • Today's Change2.00 / 2.01%
  • Shares traded93.44k
  • 1 Year change+7.61%
  • Beta-0.0353
Data delayed at least 15 minutes, as of Apr 26 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 23-Apr-24
Select bar for recommendation details.
Recommendations23-Apr-24
Buy3
Outperform7
Hold3
Underperform1
Sell0

Share price forecast in EUR

The 14 analysts offering 12 month price targets for BioMerieux SA have a median target of 114.00, with a high estimate of 128.00 and a low estimate of 90.00. The median estimate represents a 12.32% increase from the last price of 101.50.
High26.1%128.00
Med12.3%114.00
Low-11.3%90.00

Dividends in EUR

In 2023, Biomerieux SA reported a dividend of 0.85 EUR, equaling last years dividend. The 14 analysts covering the company expect dividends of 0.89 EUR for the upcoming fiscal year, an increase of 4.35%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in EUR

BioMerieux SA reported annual 2023 earnings of 3.01 per share on Mar 14, 2024.
Average growth rate+12.81%
More ▼

Revenue history & estimates in EUR

bioMerieux S.A. had revenues for the full year 2023 of 3.67bn. This was 2.39% above the prior year's results.
Average growth rate+8.39%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.